Qingdao, China--(Newsfile Corp. - July 2, 2023) - On June 30th Beijing time, Qilu Pharmaceutical Group, located in Shandong Province, China, will export more than 45000 cisplatin injections produced to the United States. This is the second batch of drugs supplied by this well-known Chinese pharmaceutical company to the United States, following the first batch of 18000 cisplatin injections exported to the United States.
Chinese company Qilu Pharmaceutical is supplying the anti-cancer drug cisplatin injection to the United States again
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8247/172145_d37568b1041379e9_001full.jpg
In March of this year, Qilu Pharmaceutical Group received an urgent email from the FDA inquiring about the availability of the anticancer drug cisplatin injection due to a shortage in the US market. Qilu Pharmaceutical Group responded quickly and had multiple rounds of communication and negotiations with the FDA. The product was declared and successfully approved in just one and a half months. On May 31st Beijing time, Qilu Pharmaceutical Group shipped 18000 bottles of cisplatin injection to the United States without affecting domestic product supply.
The FDA temporarily licensed the import of Qilu Pharmaceutical's cisplatin injection after only 1.5 months, mainly focusing on Qilu Pharmaceutical Group's comprehensive quality management system. As early as the 1990s, this company established a joint venture with a well-known Italian pharmaceutical company in Jinan. The pharmaceutical concept was the first to align with international standards, establishing a globally unified quality management and control system that meets different needs according to the requirements of different countries and regions, and achieving high-quality products throughout the production process, achieving full lifecycle management of products. Moreover, this enterprise is at the forefront of automation, intelligence, and digitization, with the world's highest quality and high-end production and testing equipment, ensuring that every product has world-class quality.
In addition, the FDA's rapid licensing of Qilu Pharmaceutical's cisplatin injection for export to the United States is related to the company's years of deep cultivation in the world's largest pharmaceutical market - the United States market. As early as 2016, Qilu Pharmaceutical Group's products entered the US market. On May 3, Beijing time, their first-line targeted specific drug Gefitinib tablets for the treatment of non-small cell lung cancer also successfully went on sale in the United States market. With the shipment of cisplatin injection to the United States, this is already the 24th formulation product of Qilu Pharmaceutical Group to achieve commercial sales in the United States.
Sun Ke
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/172145
